View ValuationMesa Laboratories 将来の成長Future 基準チェック /36Mesa Laboratoriesは、30%と4.9%でそれぞれ年率30%で利益と収益が成長すると予測される一方、EPSはgrowで27.2%年率。主要情報30.0%収益成長率27.18%EPS成長率Life Sciences 収益成長17.5%収益成長率4.9%将来の株主資本利益率n/aアナリストカバレッジLow最終更新日04 Feb 2026今後の成長に関する最新情報お知らせ • Nov 07Mesa Laboratories, Inc. Provides Revenue Guidance for the Third Quarter 2026Mesa Laboratories, Inc. provided revenue guidance for the third quarter 2026. For the quarter, the company expect revenues to sequentially increase.Price Target Changed • Aug 06Price target decreased by 13% to US$105Down from US$120, the current price target is an average from 2 analysts. New target price is 69% above last closing price of US$62.01. Stock is down 48% over the past year. The company is forecast to post earnings per share of US$1.53 next year compared to a net loss per share of US$0.36 last year.Price Target Changed • Feb 07Price target increased by 13% to US$150Up from US$133, the current price target is an average from 3 analysts. New target price is approximately in line with last closing price of US$148. Stock is up 57% over the past year. The company is forecast to post earnings per share of US$1.15 next year compared to a net loss per share of US$47.20 last year.Price Target Changed • Sep 14Price target increased by 10% to US$130Up from US$118, the current price target is an average from 3 analysts. New target price is approximately in line with last closing price of US$126. Stock is up 2.3% over the past year. The company is forecast to post earnings per share of US$1.51 next year compared to a net loss per share of US$47.20 last year.Major Estimate Revision • Mar 10Consensus EPS estimates upgraded to US$0.055 lossThe consensus outlook for fiscal year 2024 has been updated. 2024 losses forecast to reduce from -US$0.08 to -US$0.055 per share. Revenue forecast steady at US$212.8m. Life Sciences industry in the US expected to see average net income growth of 12% next year. Consensus price target of US$127 unchanged from last update. Share price rose 2.3% to US$112 over the past week.分析記事 • Feb 08Mesa Laboratories, Inc. Just Beat Earnings Expectations: Here's What Analysts Think Will Happen NextMesa Laboratories, Inc. ( NASDAQ:MLAB ) last week reported its latest third-quarter results, which makes it a good time...すべての更新を表示Recent updatesお知らせ • May 06Mesa Laboratories, Inc. to Report Q4, 2026 Results on May 27, 2026Mesa Laboratories, Inc. announced that they will report Q4, 2026 results at 6:00 AM, US Eastern Standard Time on May 27, 2026Declared Dividend • Apr 08Third quarter dividend of US$0.16 announcedDividend of US$0.16 is the same as last year. Ex-date: 29th May 2026 Payment date: 15th June 2026 Dividend yield will be 0.7%, which is higher than the industry average of 0.4%. Payout Ratios Payout ratio: 94%. Cash payout ratio: 9%.お知らせ • Apr 03Mesa Laboratories, Inc. Declares Quarterly Dividend, Payable on June 15, 2026Mesa Laboratories, Inc. announced that its Board of Directors has declared a regular quarterly dividend of $0.16 per share of common stock. The dividend will be payable on June 15, 2026, to shareholders of record at the close of business on May 29, 2026.Recent Insider Transactions • Mar 12Lead Independent Director recently bought US$253k worth of stockOn the 10th of March, Shiraz Ladiwala bought around 4k shares on-market at roughly US$72.23 per share. This transaction amounted to 70% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. Insiders have collectively bought US$190k more in shares than they have sold in the last 12 months.お知らせ • Mar 10+ 1 more updateMesa Laboratories, Inc. Announces Management Changes, Effective on or About April 13, 2026On March 3, 2026, Mesa Laboratories, Inc. initiated a leadership transition pursuant to which Gary Owens will depart as President of the Company, effective on or about April 13, 2026 (the “Transition Date”). In connection with Mr. Owens’ departure, the Board has appointed Dr. Siddhartha Kadia to serve as the Company’s new President and Chief Executive Officer, effective on or about April 13, 2026 (the “Effective Date”). The Board has also approved the appointment of Dr. Kadia as a member of the Board, effective as of the Effective Date. Dr. Kadia, age 56, is an experienced executive with over 20 years in the life sciences, diagnostics and biotechnology sectors. Since January 2025, Dr. Kadia has served as Chief Executive Officer of Calibre Scientific, a diversified global provider of life science reagents, tools, instruments, and other consumables to the lab research, diagnostics and biopharmaceutical communities. From March 2022 to August 2023, he served as Chief Executive Officer of PhenomeX and its predecessor Berkeley Lights until its acquisition by Bruker Corporation. From 2014 to 2018, he served as Chief Executive Officer of EAG Laboratories. From 2005 to 2014, he served in various roles at Life Technologies (formerly Invitrogen Corporation), including President of the company’s Life Sciences Division, until the company was acquired by Thermo Fisher Scientific. Dr. Kadia began his career at consultancy firm McKinsey & Company, where he worked from 2001 to 2005. Dr. Kadia holds a Ph.D. in Biomedical Engineering from Johns Hopkins University School of Medicine, where he was honored with the David Israel Macht Award for Excellence in Research, and a Masters of Science in Biomedical Engineering from Rutgers University.Upcoming Dividend • Feb 20Upcoming dividend of US$0.16 per shareEligible shareholders must have bought the stock before 27 February 2026. Payment date: 16 March 2026. Payout ratio is on the higher end at 94%, however this is supported by cash flows. Trailing yield: 0.7%. Lower than top quartile of American dividend payers (4.2%). In line with average of industry peers (0.6%).お知らせ • Feb 18Mesa Laboratories, Inc. Announces Renewed Commitment to Advancing Primary Standard Calibration Technology Through its DryCal Product LineMesa Laboratories, Inc. announced a renewed commitment to advancing primary standard calibration technology through its DryCal product line, as occupational health and safety professionals confront rising regulatory scrutiny and a generational workforce transition that threatens the integrity of workplace exposure monitoring. Across industries from pharmaceutical manufacturing to construction, worker safety depends on the accuracy of air sampling pumps used to measure exposure to hazardous substances. Those pumps must be calibrated to strict standards set by the Occupational Safety and Health Administration (OSHA) and the National Institute for Occupational Safety and Health (NIOSH), which require calibrator accuracy of +-1%. Yet a growing share of the calibration market relies on secondary standard instruments that can degrade to +-4-20% error at low flow rates, the very conditions most critical to detecting harmful exposures. Mesa's DryCal technology uses a proprietary piston prover, a primary standard that measures gas flow directly from fundamental SI quantities of volume and time. Unlike secondary standards, which derive flow measurements directly from pressure drop, temperature, and gas viscosity assumptions, a primary standard maintains accuracy across its full operating range without depending on environmental conditions or gas-specific properties. If contamination enters the measurement cell, the DryCal's piston stops moving before it can produce an inaccurate reading, a fail-safe design that secondary instruments, which can drift silently when compromised, do not offer. The distinction between primary and secondary standards has taken on new urgency as OSHA has chosen to standardize its own field enforcement operations on Mesa's Defender series calibrators, purchasing more than 120 units in 2025 with additional orders planned for 2026. As part of its commitment to advancing calibration education across the profession, Mesa Labs is partnering with the American Industrial Hygiene Association (AIHA) to present a webinar, "Flow Calibration Essentials for the OHS Professional," featuring Parameshwar alongside Laurence R. Durio, M.S., CIH, a certified industrial hygienist with more than 50 years of experience, including prior service with OSHA enforcement. The session addresses the science behind primary standards, regulatory requirements, and best practices for avoiding sample inspections. A recording is available through the AIHA website. Mesa's Calibration Solutions division continues to invest in education, product innovation, and expanded service capabilities to support occupational health and safety professionals worldwide. The company's mission, Protecting the V vulnerable®?, is reflected in its commitment to ensuring that the instruments behind workplace exposure decisions meet the highest standards of accuracy and defensibility.Reported Earnings • Feb 04Third quarter 2026 earnings: EPS and revenues exceed analyst expectationsThird quarter 2026 results: EPS: US$0.66 (up from US$0.31 loss in 3Q 2025). Revenue: US$65.1m (up 3.6% from 3Q 2025). Net income: US$3.63m (up US$5.31m from 3Q 2025). Profit margin: 5.6% (up from net loss in 3Q 2025). The move to profitability was primarily driven by lower expenses. Revenue exceeded analyst estimates by 3.0%. Earnings per share (EPS) also surpassed analyst estimates by 135%. Revenue is forecast to grow 4.6% p.a. on average during the next 2 years, compared to a 5.8% growth forecast for the Life Sciences industry in the US. Over the last 3 years on average, earnings per share has fallen by 14% per year but the company’s share price has fallen by 21% per year, which means it is performing significantly worse than earnings.分析記事 • Jan 11Mesa Laboratories (NASDAQ:MLAB) Has Affirmed Its Dividend Of $0.16Mesa Laboratories, Inc. ( NASDAQ:MLAB ) will pay a dividend of $0.16 on the 16th of March. The dividend yield will be...Declared Dividend • Jan 11Second quarter dividend of US$0.16 announcedDividend of US$0.16 is the same as last year. Ex-date: 27th February 2026 Payment date: 16th March 2026 Dividend yield will be 0.8%, which is higher than the industry average of 0.4%. Sustainability & Growth Dividend is being paid despite the company being loss-making over the last 12 months. However, the dividend is well covered by cash flows (10% cash payout ratio). The dividend has not increased over the past 10 years but has been stable with no material reductions to payments, indicating a long track record of dividend stability.お知らせ • Jan 08Mesa Laboratories, Inc. Declares Quarterly Dividend, Payable on March 16, 2026Mesa Laboratories, Inc. announced that its Board of Directors has declared a regular quarterly dividend of $0.16 per share of common stock. The dividend will be payable on March 16, 2026, to shareholders of record at the close of business on February 28, 2026.分析記事 • Nov 26Here's Why Mesa Laboratories (NASDAQ:MLAB) Can Manage Its Debt ResponsiblyWarren Buffett famously said, 'Volatility is far from synonymous with risk.' It's only natural to consider a company's...Seeking Alpha • Nov 25Mesa Laboratories: Appealing Territory Has Been ReachedSummary Mesa Laboratories has seen shares fall further despite stable organic growth and improved debt reduction, now trading at just over 2x sales. Valuations have become more reasonable at 14-17x earnings, but concerns remain about business diversification and reliance on adjusted earnings metrics. While leverage concerns have eased and expectations are low, Mesa Laboratories remains a higher-risk bet, but current valuation offers some support. Read the full article on Seeking AlphaUpcoming Dividend • Nov 21Upcoming dividend of US$0.16 per shareEligible shareholders must have bought the stock before 28 November 2025. Payment date: 15 December 2025. The company is not currently making a profit but it is cash flow positive. Trailing yield: 0.9%. Lower than top quartile of American dividend payers (4.6%). Higher than average of industry peers (0.5%).Reported Earnings • Nov 07Second quarter 2026 earnings: EPS exceeds analyst expectationsSecond quarter 2026 results: EPS: US$0.45 (down from US$0.63 in 2Q 2025). Revenue: US$60.7m (up 5.0% from 2Q 2025). Net income: US$2.48m (down 28% from 2Q 2025). Profit margin: 4.1% (down from 5.9% in 2Q 2025). The decrease in margin was driven by higher expenses. Revenue was in line with analyst estimates. Earnings per share (EPS) surpassed analyst estimates by 181%. Revenue is forecast to grow 4.7% p.a. on average during the next 3 years, compared to a 6.2% growth forecast for the Life Sciences industry in the US. Over the last 3 years on average, earnings per share has fallen by 42% per year but the company’s share price has only fallen by 25% per year, which means it has not declined as severely as earnings.分析記事 • Nov 07Mesa Laboratories (NASDAQ:MLAB) Has Announced A Dividend Of $0.16The board of Mesa Laboratories, Inc. ( NASDAQ:MLAB ) has announced that it will pay a dividend of $0.16 per share on...お知らせ • Nov 07Mesa Laboratories, Inc. Provides Revenue Guidance for the Third Quarter 2026Mesa Laboratories, Inc. provided revenue guidance for the third quarter 2026. For the quarter, the company expect revenues to sequentially increase.分析記事 • Oct 06Mesa Laboratories (NASDAQ:MLAB) Has Affirmed Its Dividend Of $0.16Mesa Laboratories, Inc. ( NASDAQ:MLAB ) has announced that it will pay a dividend of $0.16 per share on the 15th of...Declared Dividend • Oct 06First quarter dividend of US$0.16 announcedDividend of US$0.16 is the same as last year. Ex-date: 28th November 2025 Payment date: 15th December 2025 Dividend yield will be 0.9%, which is higher than the industry average of 0.4%. Sustainability & Growth Dividend is being paid despite the company being loss-making over the last 12 months. However, the dividend is well covered by cash flows (11% cash payout ratio). The dividend has not increased over the past 10 years but has been stable with no material reductions to payments, indicating a long track record of dividend stability.お知らせ • Oct 03+ 1 more updateMesa Laboratories, Inc. to Report Q2, 2026 Results on Nov 06, 2025Mesa Laboratories, Inc. announced that they will report Q2, 2026 results After-Market on Nov 06, 2025Upcoming Dividend • Aug 22Upcoming dividend of US$0.16 per shareEligible shareholders must have bought the stock before 29 August 2025. Payment date: 15 September 2025. The company is not currently making a profit but it is cash flow positive. Trailing yield: 0.9%. Lower than top quartile of American dividend payers (4.5%). Higher than average of industry peers (0.6%).分析記事 • Aug 20Mesa Laboratories (NASDAQ:MLAB) Is Paying Out A Dividend Of $0.16Mesa Laboratories, Inc. ( NASDAQ:MLAB ) will pay a dividend of $0.16 on the 15th of September. This means the annual...New Risk • Aug 13New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of American stocks, typically moving 11% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (11% average weekly change). Significant insider selling over the past 3 months (US$62k sold).Price Target Changed • Aug 06Price target decreased by 13% to US$105Down from US$120, the current price target is an average from 2 analysts. New target price is 69% above last closing price of US$62.01. Stock is down 48% over the past year. The company is forecast to post earnings per share of US$1.53 next year compared to a net loss per share of US$0.36 last year.Reported Earnings • Aug 05First quarter 2026 earnings: EPS exceeds analyst expectations while revenues lag behindFirst quarter 2026 results: EPS: US$0.87 (up from US$0.63 in 1Q 2025). Revenue: US$59.5m (up 2.4% from 1Q 2025). Net income: US$4.74m (up 40% from 1Q 2025). Profit margin: 8.0% (up from 5.8% in 1Q 2025). Revenue missed analyst estimates by 1.7%. Earnings per share (EPS) exceeded analyst estimates by 95%. Revenue is forecast to grow 4.6% p.a. on average during the next 2 years, compared to a 6.0% growth forecast for the Life Sciences industry in the US. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 37 percentage points per year, which is a significant difference in performance.分析記事 • Jul 20It's Down 27% But Mesa Laboratories, Inc. (NASDAQ:MLAB) Could Be Riskier Than It LooksUnfortunately for some shareholders, the Mesa Laboratories, Inc. ( NASDAQ:MLAB ) share price has dived 27% in the last...分析記事 • Jul 15Mesa Laboratories (NASDAQ:MLAB) Is Due To Pay A Dividend Of $0.16The board of Mesa Laboratories, Inc. ( NASDAQ:MLAB ) has announced that it will pay a dividend of $0.16 per share on...お知らせ • Jul 14Mesa Laboratories, Inc., Annual General Meeting, Aug 22, 2025Mesa Laboratories, Inc., Annual General Meeting, Aug 22, 2025. Location: mesa laboratories, lakewood, colorado 80228, United States分析記事 • Jul 07Mesa Laboratories, Inc.'s (NASDAQ:MLAB) Intrinsic Value Is Potentially 32% Above Its Share PriceKey Insights The projected fair value for Mesa Laboratories is US$136 based on 2 Stage Free Cash Flow to Equity Mesa...Declared Dividend • Jul 06Fourth quarter dividend of US$0.16 announcedDividend of US$0.16 is the same as last year. Ex-date: 29th August 2025 Payment date: 15th September 2025 Dividend yield will be 0.6%, which is higher than the industry average of 0.4%.お知らせ • Jul 04Mesa Labs Declares Quarterly Dividend, Payable on September 15, 2025Mesa Laboratories, Inc. announced that its Board of Directors has declared a regular quarterly dividend of $0.16 per share of common stock. The dividend will be payable on September 15, 2025, to shareholders of record at the close of business on August 29, 2025.お知らせ • Jul 03Mesa Laboratories, Inc. to Report Q1, 2026 Results on Aug 05, 2025Mesa Laboratories, Inc. announced that they will report Q1, 2026 results at 8:00 AM, US Eastern Standard Time on Aug 05, 2025Board Change • Jul 01Insufficient new directorsThere is 1 new director who has joined the board in the last 3 years. The company's board is composed of: 1 new director. 5 experienced directors. 1 highly experienced director. Independent Director Mark Capone was the last director to join the board, commencing their role in 2024. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.お知らせ • Jun 30+ 7 more updatesMesa Laboratories, Inc.(NasdaqGS:MLAB) dropped from Russell 2000 Value IndexMesa Laboratories, Inc.(NasdaqGS:MLAB) dropped from Russell 2000 Value IndexRecent Insider Transactions Derivative • Jun 18CEO, President & Director notifies of intention to sell stockGary Owens intends to sell 2k shares in the next 90 days after lodging an Intent To Sell Form on the 16th of June. If the sale is conducted around the recent share price of US$97.12, it would amount to US$188k. For the year to March 2019, Gary's total compensation was 14% salary and 86% other compensation. This indicates that these sales could comprise a meaningful part of their income for the year. Since September 2024, Gary's direct individual holding has increased from 36.85k shares to 43.34k. Company insiders have collectively sold US$897k more than they bought, via options and on-market transactions in the last 12 months.分析記事 • Jun 18We Think Mesa Laboratories (NASDAQ:MLAB) Can Stay On Top Of Its DebtLegendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...Reported Earnings • May 29Full year 2025 earnings: EPS misses analyst expectationsFull year 2025 results: US$0.36 loss per share (improved from US$47.21 loss in FY 2024). Revenue: US$241.0m (up 12% from FY 2024). Net loss: US$1.97m (loss narrowed 99% from FY 2024). Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates. Revenue is forecast to grow 5.0% p.a. on average during the next 2 years, compared to a 6.1% growth forecast for the Life Sciences industry in the US. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 77 percentage points per year, which is a significant difference in performance.Upcoming Dividend • May 23Upcoming dividend of US$0.16 per shareEligible shareholders must have bought the stock before 30 May 2025. Payment date: 16 June 2025. The company is not currently making a profit but it is cash flow positive. Trailing yield: 0.6%. Lower than top quartile of American dividend payers (4.8%). In line with average of industry peers (0.7%).Declared Dividend • Apr 14Third quarter dividend of US$0.16 announcedDividend of US$0.16 is the same as last year. Ex-date: 30th May 2025 Payment date: 16th June 2025 Dividend yield will be 0.6%, which is higher than the industry average of 0.4%.お知らせ • Apr 08Mesa Laboratories, Inc. Declares Quarterly Dividend, Payable on June 16, 2025Mesa Laboratories, Inc. announced that its Board of Directors has declared a regular quarterly dividend of $0.16 per share of common stock. The dividend will be payable on June 16, 2025, to shareholders of record at the close of business on May 30, 2025.分析記事 • Apr 01Investors Interested In Mesa Laboratories, Inc.'s (NASDAQ:MLAB) RevenuesWith a median price-to-sales (or "P/S") ratio of close to 2.7x in the Life Sciences industry in the United States, you...Recent Insider Transactions Derivative • Mar 20CEO, President & Director notifies of intention to sell stockGary Owens intends to sell 21k shares in the next 90 days after lodging an Intent To Sell Form on the 19th of March. If the sale is conducted around the recent share price of US$124, it would amount to US$2.6m. For the year to March 2018, Gary's total compensation was 14% salary and 86% other compensation. This indicates that these sales could comprise a meaningful part of their income for the year. Since June 2024, Gary's direct individual holding has decreased from 114.93k shares to 43.34k. Company insiders have collectively sold US$967k more than they bought, via options and on-market transactions in the last 12 months.分析記事 • Feb 28At US$135, Is Mesa Laboratories, Inc. (NASDAQ:MLAB) Worth Looking At Closely?Mesa Laboratories, Inc. ( NASDAQ:MLAB ), might not be a large cap stock, but it saw a significant share price rise of...Upcoming Dividend • Feb 21Upcoming dividend of US$0.16 per shareEligible shareholders must have bought the stock before 28 February 2025. Payment date: 17 March 2025. The company is not currently making a profit but it is cash flow positive. Trailing yield: 0.5%. Lower than top quartile of American dividend payers (4.5%). In line with average of industry peers (0.6%).Price Target Changed • Feb 07Price target increased by 13% to US$150Up from US$133, the current price target is an average from 3 analysts. New target price is approximately in line with last closing price of US$148. Stock is up 57% over the past year. The company is forecast to post earnings per share of US$1.15 next year compared to a net loss per share of US$47.20 last year.Reported Earnings • Feb 04Third quarter 2025 earnings: Revenues exceed analysts expectations while EPS lags behindThird quarter 2025 results: US$0.31 loss per share (down from US$0.39 profit in 3Q 2024). Revenue: US$62.8m (up 18% from 3Q 2024). Net loss: US$1.68m (down 179% from profit in 3Q 2024). Revenue exceeded analyst estimates by 6.8%. Earnings per share (EPS) missed analyst estimates. Revenue is forecast to grow 5.0% p.a. on average during the next 3 years, compared to a 5.9% growth forecast for the Life Sciences industry in the US. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 106 percentage points per year, which is a significant difference in performance.お知らせ • Jan 19Mesa Laboratories, Inc. to Report Q3, 2025 Results on Feb 04, 2025Mesa Laboratories, Inc. announced that they will report Q3, 2025 results at 8:00 AM, Eastern Standard Time on Feb 04, 2025Declared Dividend • Jan 10Second quarter dividend of US$0.16 announcedDividend of US$0.16 is the same as last year. Ex-date: 28th February 2025 Payment date: 17th March 2025 Dividend yield will be 0.5%, which is about the same as the industry average.分析記事 • Jan 07Mesa Laboratories, Inc. (NASDAQ:MLAB) Shares Could Be 22% Below Their Intrinsic Value EstimateKey Insights Mesa Laboratories' estimated fair value is US$184 based on 2 Stage Free Cash Flow to Equity Current share...お知らせ • Jan 07Mesa Laboratories, Inc. Declares Quarterly Dividend, Payable on March 17, 2025Mesa Laboratories, Inc. announced that its Board of Directors has declared a regular quarterly dividend of $0.16 per share of common stock. The dividend will be payable on March 17, 2025, to shareholders of record at the close of business on February 28, 2025.Seeking Alpha • Dec 19Mesa Laboratories: GKE Acquisition New Crown Jewel, Still Doesn't Move The NeedleSummary Mesa Laboratories' recent acquisition of GKE has improved ROICs, but the legacy business remains a drag on overall performance. Despite improvements, MLAB's valuation risks compression, trading at over 60x trailing EBIT, with an intrinsic worth estimated at $130–145/share. I reiterate a hold rating, with the view the Company is not yet at a turning point, despite promising developments from the GKE acquisition. Read the full article on Seeking AlphaUpcoming Dividend • Nov 22Upcoming dividend of US$0.16 per shareEligible shareholders must have bought the stock before 29 November 2024. Payment date: 16 December 2024. The company is not currently making a profit but it is cash flow positive. Trailing yield: 0.6%. Lower than top quartile of American dividend payers (4.3%). In line with average of industry peers (0.5%).分析記事 • Nov 20Investors Give Mesa Laboratories, Inc. (NASDAQ:MLAB) Shares A 25% HidingMesa Laboratories, Inc. ( NASDAQ:MLAB ) shareholders that were waiting for something to happen have been dealt a blow...Reported Earnings • Nov 08Second quarter 2025 earnings: EPS exceeds analyst expectationsSecond quarter 2025 results: EPS: US$0.63 (up from US$0.23 loss in 2Q 2024). Revenue: US$57.8m (up 8.8% from 2Q 2024). Net income: US$3.43m (up US$4.66m from 2Q 2024). Profit margin: 5.9% (up from net loss in 2Q 2024). Revenue was in line with analyst estimates. Earnings per share (EPS) surpassed analyst estimates significantly. Revenue is forecast to grow 4.4% p.a. on average during the next 3 years, compared to a 6.5% growth forecast for the Life Sciences industry in the US. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 112 percentage points per year, which is a significant difference in performance.Recent Insider Transactions • Nov 01CEO, President & Director recently sold US$572k worth of stockOn the 29th of October, Gary Owens sold around 5k shares on-market at roughly US$113 per share. This transaction amounted to 10% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. This was Gary's only on-market trade for the last 12 months.Recent Insider Transactions Derivative • Oct 30CEO, President & Director notifies of intention to sell stockGary Owens intends to sell 3k shares in the next 90 days after lodging an Intent To Sell Form on the 28th of October. If the sale is conducted around the recent share price of US$114, it would amount to US$286k. For the year to March 2018, Gary's total compensation was 14% salary and 86% other compensation. This indicates that these sales could comprise a meaningful part of their income for the year. Since June 2024, Gary's direct individual holding has decreased from 114.93k shares to 36.85k. Company insiders have collectively sold US$395k more than they bought, via options and on-market transactions in the last 12 months.分析記事 • Oct 17We Think Mesa Laboratories (NASDAQ:MLAB) Can Stay On Top Of Its DebtLegendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...Declared Dividend • Oct 06First quarter dividend of US$0.16 announcedDividend of US$0.16 is the same as last year. Ex-date: 29th November 2024 Payment date: 16th December 2024 Dividend yield will be 0.5%, which is higher than the industry average of 0.4%.お知らせ • Oct 03Mesa Laboratories, Inc. Declares Quarterly Dividend, Payable on December 16, 2024Mesa Laboratories, Inc. announced that its Board of Directors has declared a regular quarterly dividend of $0.16 per share of common stock. The dividend will be payable on December 16, 2024, to shareholders of record at the close of business on November 29, 2024.Recent Insider Transactions Derivative • Sep 16Insider notifies of intention to sell stockBrian Archbold intends to sell 1k shares in the next 90 days after lodging an Intent To Sell Form on the 13th of September. If the sale is conducted around the recent share price of US$125, it would amount to US$187k. Since December 2023, Brian's direct individual holding has increased from 558.00 shares to 1.50k. Company insiders have collectively sold US$395k more than they bought, via options and on-market transactions in the last 12 months.Price Target Changed • Sep 14Price target increased by 10% to US$130Up from US$118, the current price target is an average from 3 analysts. New target price is approximately in line with last closing price of US$126. Stock is up 2.3% over the past year. The company is forecast to post earnings per share of US$1.51 next year compared to a net loss per share of US$47.20 last year.分析記事 • Jul 29A Piece Of The Puzzle Missing From Mesa Laboratories, Inc.'s (NASDAQ:MLAB) 27% Share Price ClimbMesa Laboratories, Inc. ( NASDAQ:MLAB ) shareholders would be excited to see that the share price has had a great...Declared Dividend • Jul 29Fourth quarter dividend of US$0.16 announcedDividend of US$0.16 is the same as last year. Ex-date: 30th August 2024 Payment date: 16th September 2024 Dividend yield will be 0.6%, which is higher than the industry average of 0.4%.お知らせ • Jul 22Mesa Laboratories, Inc., Annual General Meeting, Aug 30, 2024Mesa Laboratories, Inc., Annual General Meeting, Aug 30, 2024. Location: corporate headquarters at 12100 west sixth avenue, lakewood, colorado 80228., United Statesお知らせ • Jul 09Mesa Laboratories, Inc. Declares Quarterly Dividend, Payable on September 16, 2024Mesa Laboratories, Inc. announced that its Board of Directors have declared a regular quarterly dividend of $0.16 per share of common stock. The dividend will be payable on September 16, 2024, to shareholders of record at the close of business on August 30, 2024.Reported Earnings • Jun 06Full year 2024 earnings: Revenues exceed analysts expectations while EPS lags behindFull year 2024 results: US$47.21 loss per share (down from US$0.17 profit in FY 2023). Revenue: US$216.2m (down 1.3% from FY 2023). Net loss: US$254.2m (down US$255.2m from profit in FY 2023). Revenue exceeded analyst estimates by 2.1%. Earnings per share (EPS) missed analyst estimates significantly. Revenue is forecast to grow 7.2% p.a. on average during the next 3 years, compared to a 6.6% growth forecast for the Life Sciences industry in the US. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 133 percentage points per year, which is a significant difference in performance.お知らせ • Jun 06Mesa Laboratories, Inc. Reports Impairment of Goodwill and Long-Lived Assets for the Fourth Quarter Ended March 31, 2024Mesa Laboratories, Inc. reported Impairment of goodwill and long-lived assets for the fourth quarter ended March 31, 2024 of $274,533,000.Upcoming Dividend • May 24Upcoming dividend of US$0.16 per shareEligible shareholders must have bought the stock before 31 May 2024. Payment date: 14 June 2024. The company is paying out more than 100% of its profits but is generating plenty of cash to support the dividend. Trailing yield: 0.6%. Lower than top quartile of American dividend payers (4.7%). Higher than average of industry peers (0.3%).分析記事 • May 03Is Now An Opportune Moment To Examine Mesa Laboratories, Inc. (NASDAQ:MLAB)?While Mesa Laboratories, Inc. ( NASDAQ:MLAB ) might not have the largest market cap around , it received a lot of...Declared Dividend • Apr 08Third quarter dividend of US$0.16 announcedDividend of US$0.16 is the same as last year. Ex-date: 31st May 2024 Payment date: 14th June 2024 Dividend yield will be 0.6%, which is higher than the industry average of 0.4%. Payout Ratios Payout ratio: 363%. Cash payout ratio: 8%.お知らせ • Apr 05Mesa Laboratories, Inc. Declares Regular Quarterly Dividend, Payable on June 14, 2024Mesa Laboratories, Inc. announced that its board of directors has declared a regular quarterly dividend of $0.16 per share of common stock. The dividend will be payable on June 14, 2024, to shareholders of record at the close of business on May 31, 2024.お知らせ • Apr 02Mesa Laboratories, Inc. to Report Q4, 2024 Results on May 24, 2024Mesa Laboratories, Inc. announced that they will report Q4, 2024 results at 8:00 AM, US Eastern Standard Time on May 24, 2024分析記事 • Mar 15Is Mesa Laboratories (NASDAQ:MLAB) Using Too Much Debt?Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...Major Estimate Revision • Mar 10Consensus EPS estimates upgraded to US$0.055 lossThe consensus outlook for fiscal year 2024 has been updated. 2024 losses forecast to reduce from -US$0.08 to -US$0.055 per share. Revenue forecast steady at US$212.8m. Life Sciences industry in the US expected to see average net income growth of 12% next year. Consensus price target of US$127 unchanged from last update. Share price rose 2.3% to US$112 over the past week.Upcoming Dividend • Feb 21Upcoming dividend of US$0.16 per shareEligible shareholders must have bought the stock before 28 February 2024. Payment date: 15 March 2024. The company is paying out more than 100% of its profits but is generating plenty of cash to support the dividend. Trailing yield: 0.6%. Lower than top quartile of American dividend payers (4.7%). Higher than average of industry peers (0.4%).分析記事 • Feb 08Mesa Laboratories, Inc. Just Beat Earnings Expectations: Here's What Analysts Think Will Happen NextMesa Laboratories, Inc. ( NASDAQ:MLAB ) last week reported its latest third-quarter results, which makes it a good time...New Risk • Feb 07New minor risk - Earnings qualityThe company has large one-off items impacting its financial results. One-off items were 154% of the size of the rest of the company's trailing 12-month earnings before tax. This is considered a minor risk. One-off items are incomes or expenses that the company does not expect to repeat in future periods. Examples include profits from the sale of a business or expenses from a restructuring or legal settlements. If the company's reported statutory earnings include a large proportion of one-off items it means they may be an unreliable indicator of its true business performance as the earnings were skewed by these incomes or expenses. Currently, the following risks have been identified for the company: Major Risk Interest payments are not well covered by earnings (0.3x net interest cover). Minor Risk Large one-off items impacting financial results.Reported Earnings • Feb 05Third quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behindThird quarter 2024 results: EPS: US$0.39 (up from US$0.084 in 3Q 2023). Revenue: US$53.5m (down 1.5% from 3Q 2023). Net income: US$2.12m (up 369% from 3Q 2023). Profit margin: 4.0% (up from 0.8% in 3Q 2023). The increase in margin was driven by lower expenses. Revenue missed analyst estimates by 2.1%. Earnings per share (EPS) exceeded analyst estimates significantly. Revenue is forecast to grow 9.2% p.a. on average during the next 3 years, compared to a 6.1% growth forecast for the Life Sciences industry in the US. Over the last 3 years on average, earnings per share has fallen by 37% per year but the company’s share price has only fallen by 29% per year, which means it has not declined as severely as earnings.お知らせ • Jan 08Mesa Laboratories, Inc. Appoints Mark Capone to Its Board of DirectorsMesa Laboratories, Inc. announced the appointment of Mark Capone to its Board of Directors, effective January 5, 2024. Following Mr. Capone’s election, the Mesa Board will be comprised of 7 directors, the majority of whom are independent. The Board is committed to ongoing director refreshment and continues to consider new, qualified independent directors. Mr. Capone most recently served as CEO and President of Myriad Genetics for five years. Prior to his appointment as CEO and President, he held various progressive leadership roles at Myriad Genetics, with a total tenure of 17 years at the company. During his leadership tenure, he oversaw Myriad Genetics’ growth from an early-stage pioneer in molecular diagnostics into a leading global precision medicine company. Prior to his tenure at Myriad Genetics, Mr. Capone spent 17 years with Eli Lilly and Company in positions across the entire value chain. In addition to his executive leadership positions, Mr. Capone is a Non-Executive Director and member of the Compensation Committee for of Owlstone Medical Ltd, a breath biopsy diagnostic company focused on early detection of cancer and precision medicine, and a Non-Executive Director and member of the Audit Committee and Financing Committee of DermTech, a U.S. based company focused on early melanoma detection and other skin applications. Previously, Mr. Capone was a director at Abcam PLC, helping to guide that company through its acquisition by Danaher Corporation. Mr. Capone holds a Bachelor of Science in Chemical Engineering from Pennsylvania State University and a M.Sc. in Management and a M.Sc.in Chemical Engineering from Massachusetts Institute of Technology.お知らせ • Jan 05Mesa Laboratories, Inc. Declares Regular Quarterly Dividend, Payable on March 15, 2024Mesa Laboratories, Inc. announced that on January 2, 2024 its Board of Directors declared a regular quarterly dividend of $0.16 per share of common stock. The dividend will be payable on March 15, 2024, to shareholders of record at the close of business on February 29, 2024.Recent Insider Transactions Derivative • Dec 18Insider notifies of intention to sell stockBrian Archbold intends to sell 2k shares in the next 90 days after lodging an Intent To Sell Form on the 15th of December. If the sale is conducted around the recent share price of US$116, it would amount to US$174k. Since June 2023, Brian has owned 9.65k shares directly. Company insiders have collectively sold US$1.5m more than they bought, via options and on-market transactions in the last 12 months.お知らせ • Dec 15Mesa Laboratories, Inc. to Report Q3, 2024 Results on Feb 05, 2024Mesa Laboratories, Inc. announced that they will report Q3, 2024 results at 8:00 AM, US Eastern Standard Time on Feb 05, 2024分析記事 • Dec 05Is Mesa Laboratories, Inc. (NASDAQ:MLAB) Trading At A 43% Discount?Key Insights The projected fair value for Mesa Laboratories is US$166 based on 2 Stage Free Cash Flow to Equity Mesa...Upcoming Dividend • Nov 22Upcoming dividend of US$0.16 per share at 0.7% yieldEligible shareholders must have bought the stock before 29 November 2023. Payment date: 15 December 2023. The company is not currently making a profit but it is cash flow positive. Trailing yield: 0.7%. Lower than top quartile of American dividend payers (4.9%). Higher than average of industry peers (0.4%).Price Target Changed • Nov 09Price target decreased by 17% to US$115Down from US$139, the current price target is an average from 2 analysts. New target price is 23% above last closing price of US$93.73. Stock is down 45% over the past year. The company posted earnings per share of US$0.17 last year.Reported Earnings • Nov 07Second quarter 2024 earnings: EPS and revenues miss analyst expectationsSecond quarter 2024 results: US$0.23 loss per share (down from US$0.24 profit in 2Q 2023). Revenue: US$53.2m (down 9.5% from 2Q 2023). Net loss: US$1.23m (down 194% from profit in 2Q 2023). Revenue missed analyst estimates by 2.7%. Earnings per share (EPS) were also behind analyst expectations. Revenue is forecast to grow 8.6% p.a. on average during the next 3 years, compared to a 3.9% growth forecast for the Life Sciences industry in the US. Over the last 3 years on average, earnings per share has fallen by 17% per year but the company’s share price has fallen by 30% per year, which means it is performing significantly worse than earnings.お知らせ • Oct 18Mesa Laboratories, Inc. (NasdaqGS:MLAB) entered into a definitive agreement to acquire Beijing GKE Science & Technology Co. LTD for €5 million.Mesa Laboratories, Inc. (NasdaqGS:MLAB) entered into a definitive agreement to acquire Beijing GKE Science & Technology Co. LTD for €5 million on October 16, 2023. The total purchase price for the acquisition of the entity along with other 2 entities is €85 million, subject to customary purchase price adjustments and holdbacks. Collectively the three entities are referred to as “GKE”. The transactions were or will be funded with proceeds from our credit facility and cash on hand. The transaction is subject to customary conditions, including receipt of applicable Chinese regulatory approvals and is expected to be completed during our third quarter ending December 31, 2023.お知らせ • Oct 17Mesa Laboratories, Inc. (NasdaqGS:MLAB) acquired Sterilization indicators business of GKE-GmbH and SAL GmbH from Gke-GmbH for €80 million.Mesa Laboratories, Inc. (NasdaqGS:MLAB) acquired Sterilization indicators business of GKE-GmbH and SAL GmbH from Gke-GmbH for €80 million on October 16, 2023. The consideration will be paid in cash and will be funded with proceeds from credit facility and cash on hand. In a related transaction Mesa Laboratories, Inc. (NasdaqGS:MLAB) will acquire Beijing GKE Science & Technology Co. LTD for €5 million. Mesa Laboratories, Inc. (NasdaqGS:MLAB) completed the acquisition of Sterilization indicators business of GKE-GmbH and SAL GmbH from Gke-GmbH on October 16, 2023.Price Target Changed • Oct 05Price target decreased by 8.9% to US$139Down from US$153, the current price target is an average from 2 analysts. New target price is 40% above last closing price of US$98.95. Stock is down 31% over the past year. The company is forecast to post earnings per share of US$0.68 for next year compared to US$0.17 last year.業績と収益の成長予測NasdaqGS:MLAB - アナリストの将来予測と過去の財務データ ( )USD Millions日付収益収益フリー・キャッシュフロー営業活動によるキャッシュ平均アナリスト数3/31/202726310444933/31/2026251133741312/31/202524843842N/A9/30/2025245-23741N/A6/30/2025242-13338N/A3/31/2025241-24247N/A12/31/2024238-2494347N/A9/30/2024228-2463640N/A6/30/2024224-2504245N/A3/31/2024216-2544244N/A12/31/202321314144N/A9/30/2023214-13640N/A6/30/202321923641N/A3/31/202321912328N/A12/31/2022222-12025N/A9/30/2022223-42833N/A6/30/2022200-22327N/A3/31/202218423539N/A12/31/202116383943N/A9/30/202114353638N/A6/30/202113944244N/A3/31/202113433537N/A12/31/2020130-23132N/A9/30/2020128-23132N/A6/30/2020121-22729N/A3/31/202011822527N/A12/31/201911052728N/A9/30/201910510N/A28N/A6/30/20191048N/A25N/A3/31/20191037N/A31N/A12/31/201810410N/A30N/A9/30/2018101-2N/A29N/A6/30/2018990N/A30N/A3/31/201896-3N/A26N/A12/31/201794-4N/A17N/A9/30/20179411N/A14N/A6/30/20179511N/A7N/A3/31/20179411N/A17N/A12/31/20169412N/A14N/A9/30/20169011N/A9N/A6/30/20168810N/A18N/A3/31/20168511N/A17N/A12/31/2015789N/A15N/A9/30/2015769N/A16N/A6/30/20157310N/A13N/Aもっと見るアナリストによる今後の成長予測収入対貯蓄率: MLABの予測収益成長率 (年間30% ) は 貯蓄率 ( 3.5% ) を上回っています。収益対市場: MLABの収益 ( 30% ) はUS市場 ( 16.7% ) よりも速いペースで成長すると予測されています。高成長収益: MLABの収益は今後 3 年間で 大幅に 増加すると予想されています。収益対市場: MLABの収益 ( 4.9% ) US市場 ( 11.6% ) よりも低い成長が予測されています。高い収益成長: MLABの収益 ( 4.9% ) 20%よりも低い成長が予測されています。一株当たり利益成長率予想将来の株主資本利益率将来のROE: MLABの 自己資本利益率 が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です成長企業の発掘7D1Y7D1Y7D1YPharmaceuticals-biotech 業界の高成長企業。View Past Performance企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/05/11 23:09終値2026/05/11 00:00収益2025/12/31年間収益2025/03/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Mesa Laboratories, Inc. 3 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。7 アナリスト機関Paul KnightBrean Capital Historical (Janney Montgomery)Vijay KumarEvercore ISITycho PetersonJefferies LLC4 その他のアナリストを表示
お知らせ • Nov 07Mesa Laboratories, Inc. Provides Revenue Guidance for the Third Quarter 2026Mesa Laboratories, Inc. provided revenue guidance for the third quarter 2026. For the quarter, the company expect revenues to sequentially increase.
Price Target Changed • Aug 06Price target decreased by 13% to US$105Down from US$120, the current price target is an average from 2 analysts. New target price is 69% above last closing price of US$62.01. Stock is down 48% over the past year. The company is forecast to post earnings per share of US$1.53 next year compared to a net loss per share of US$0.36 last year.
Price Target Changed • Feb 07Price target increased by 13% to US$150Up from US$133, the current price target is an average from 3 analysts. New target price is approximately in line with last closing price of US$148. Stock is up 57% over the past year. The company is forecast to post earnings per share of US$1.15 next year compared to a net loss per share of US$47.20 last year.
Price Target Changed • Sep 14Price target increased by 10% to US$130Up from US$118, the current price target is an average from 3 analysts. New target price is approximately in line with last closing price of US$126. Stock is up 2.3% over the past year. The company is forecast to post earnings per share of US$1.51 next year compared to a net loss per share of US$47.20 last year.
Major Estimate Revision • Mar 10Consensus EPS estimates upgraded to US$0.055 lossThe consensus outlook for fiscal year 2024 has been updated. 2024 losses forecast to reduce from -US$0.08 to -US$0.055 per share. Revenue forecast steady at US$212.8m. Life Sciences industry in the US expected to see average net income growth of 12% next year. Consensus price target of US$127 unchanged from last update. Share price rose 2.3% to US$112 over the past week.
分析記事 • Feb 08Mesa Laboratories, Inc. Just Beat Earnings Expectations: Here's What Analysts Think Will Happen NextMesa Laboratories, Inc. ( NASDAQ:MLAB ) last week reported its latest third-quarter results, which makes it a good time...
お知らせ • May 06Mesa Laboratories, Inc. to Report Q4, 2026 Results on May 27, 2026Mesa Laboratories, Inc. announced that they will report Q4, 2026 results at 6:00 AM, US Eastern Standard Time on May 27, 2026
Declared Dividend • Apr 08Third quarter dividend of US$0.16 announcedDividend of US$0.16 is the same as last year. Ex-date: 29th May 2026 Payment date: 15th June 2026 Dividend yield will be 0.7%, which is higher than the industry average of 0.4%. Payout Ratios Payout ratio: 94%. Cash payout ratio: 9%.
お知らせ • Apr 03Mesa Laboratories, Inc. Declares Quarterly Dividend, Payable on June 15, 2026Mesa Laboratories, Inc. announced that its Board of Directors has declared a regular quarterly dividend of $0.16 per share of common stock. The dividend will be payable on June 15, 2026, to shareholders of record at the close of business on May 29, 2026.
Recent Insider Transactions • Mar 12Lead Independent Director recently bought US$253k worth of stockOn the 10th of March, Shiraz Ladiwala bought around 4k shares on-market at roughly US$72.23 per share. This transaction amounted to 70% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. Insiders have collectively bought US$190k more in shares than they have sold in the last 12 months.
お知らせ • Mar 10+ 1 more updateMesa Laboratories, Inc. Announces Management Changes, Effective on or About April 13, 2026On March 3, 2026, Mesa Laboratories, Inc. initiated a leadership transition pursuant to which Gary Owens will depart as President of the Company, effective on or about April 13, 2026 (the “Transition Date”). In connection with Mr. Owens’ departure, the Board has appointed Dr. Siddhartha Kadia to serve as the Company’s new President and Chief Executive Officer, effective on or about April 13, 2026 (the “Effective Date”). The Board has also approved the appointment of Dr. Kadia as a member of the Board, effective as of the Effective Date. Dr. Kadia, age 56, is an experienced executive with over 20 years in the life sciences, diagnostics and biotechnology sectors. Since January 2025, Dr. Kadia has served as Chief Executive Officer of Calibre Scientific, a diversified global provider of life science reagents, tools, instruments, and other consumables to the lab research, diagnostics and biopharmaceutical communities. From March 2022 to August 2023, he served as Chief Executive Officer of PhenomeX and its predecessor Berkeley Lights until its acquisition by Bruker Corporation. From 2014 to 2018, he served as Chief Executive Officer of EAG Laboratories. From 2005 to 2014, he served in various roles at Life Technologies (formerly Invitrogen Corporation), including President of the company’s Life Sciences Division, until the company was acquired by Thermo Fisher Scientific. Dr. Kadia began his career at consultancy firm McKinsey & Company, where he worked from 2001 to 2005. Dr. Kadia holds a Ph.D. in Biomedical Engineering from Johns Hopkins University School of Medicine, where he was honored with the David Israel Macht Award for Excellence in Research, and a Masters of Science in Biomedical Engineering from Rutgers University.
Upcoming Dividend • Feb 20Upcoming dividend of US$0.16 per shareEligible shareholders must have bought the stock before 27 February 2026. Payment date: 16 March 2026. Payout ratio is on the higher end at 94%, however this is supported by cash flows. Trailing yield: 0.7%. Lower than top quartile of American dividend payers (4.2%). In line with average of industry peers (0.6%).
お知らせ • Feb 18Mesa Laboratories, Inc. Announces Renewed Commitment to Advancing Primary Standard Calibration Technology Through its DryCal Product LineMesa Laboratories, Inc. announced a renewed commitment to advancing primary standard calibration technology through its DryCal product line, as occupational health and safety professionals confront rising regulatory scrutiny and a generational workforce transition that threatens the integrity of workplace exposure monitoring. Across industries from pharmaceutical manufacturing to construction, worker safety depends on the accuracy of air sampling pumps used to measure exposure to hazardous substances. Those pumps must be calibrated to strict standards set by the Occupational Safety and Health Administration (OSHA) and the National Institute for Occupational Safety and Health (NIOSH), which require calibrator accuracy of +-1%. Yet a growing share of the calibration market relies on secondary standard instruments that can degrade to +-4-20% error at low flow rates, the very conditions most critical to detecting harmful exposures. Mesa's DryCal technology uses a proprietary piston prover, a primary standard that measures gas flow directly from fundamental SI quantities of volume and time. Unlike secondary standards, which derive flow measurements directly from pressure drop, temperature, and gas viscosity assumptions, a primary standard maintains accuracy across its full operating range without depending on environmental conditions or gas-specific properties. If contamination enters the measurement cell, the DryCal's piston stops moving before it can produce an inaccurate reading, a fail-safe design that secondary instruments, which can drift silently when compromised, do not offer. The distinction between primary and secondary standards has taken on new urgency as OSHA has chosen to standardize its own field enforcement operations on Mesa's Defender series calibrators, purchasing more than 120 units in 2025 with additional orders planned for 2026. As part of its commitment to advancing calibration education across the profession, Mesa Labs is partnering with the American Industrial Hygiene Association (AIHA) to present a webinar, "Flow Calibration Essentials for the OHS Professional," featuring Parameshwar alongside Laurence R. Durio, M.S., CIH, a certified industrial hygienist with more than 50 years of experience, including prior service with OSHA enforcement. The session addresses the science behind primary standards, regulatory requirements, and best practices for avoiding sample inspections. A recording is available through the AIHA website. Mesa's Calibration Solutions division continues to invest in education, product innovation, and expanded service capabilities to support occupational health and safety professionals worldwide. The company's mission, Protecting the V vulnerable®?, is reflected in its commitment to ensuring that the instruments behind workplace exposure decisions meet the highest standards of accuracy and defensibility.
Reported Earnings • Feb 04Third quarter 2026 earnings: EPS and revenues exceed analyst expectationsThird quarter 2026 results: EPS: US$0.66 (up from US$0.31 loss in 3Q 2025). Revenue: US$65.1m (up 3.6% from 3Q 2025). Net income: US$3.63m (up US$5.31m from 3Q 2025). Profit margin: 5.6% (up from net loss in 3Q 2025). The move to profitability was primarily driven by lower expenses. Revenue exceeded analyst estimates by 3.0%. Earnings per share (EPS) also surpassed analyst estimates by 135%. Revenue is forecast to grow 4.6% p.a. on average during the next 2 years, compared to a 5.8% growth forecast for the Life Sciences industry in the US. Over the last 3 years on average, earnings per share has fallen by 14% per year but the company’s share price has fallen by 21% per year, which means it is performing significantly worse than earnings.
分析記事 • Jan 11Mesa Laboratories (NASDAQ:MLAB) Has Affirmed Its Dividend Of $0.16Mesa Laboratories, Inc. ( NASDAQ:MLAB ) will pay a dividend of $0.16 on the 16th of March. The dividend yield will be...
Declared Dividend • Jan 11Second quarter dividend of US$0.16 announcedDividend of US$0.16 is the same as last year. Ex-date: 27th February 2026 Payment date: 16th March 2026 Dividend yield will be 0.8%, which is higher than the industry average of 0.4%. Sustainability & Growth Dividend is being paid despite the company being loss-making over the last 12 months. However, the dividend is well covered by cash flows (10% cash payout ratio). The dividend has not increased over the past 10 years but has been stable with no material reductions to payments, indicating a long track record of dividend stability.
お知らせ • Jan 08Mesa Laboratories, Inc. Declares Quarterly Dividend, Payable on March 16, 2026Mesa Laboratories, Inc. announced that its Board of Directors has declared a regular quarterly dividend of $0.16 per share of common stock. The dividend will be payable on March 16, 2026, to shareholders of record at the close of business on February 28, 2026.
分析記事 • Nov 26Here's Why Mesa Laboratories (NASDAQ:MLAB) Can Manage Its Debt ResponsiblyWarren Buffett famously said, 'Volatility is far from synonymous with risk.' It's only natural to consider a company's...
Seeking Alpha • Nov 25Mesa Laboratories: Appealing Territory Has Been ReachedSummary Mesa Laboratories has seen shares fall further despite stable organic growth and improved debt reduction, now trading at just over 2x sales. Valuations have become more reasonable at 14-17x earnings, but concerns remain about business diversification and reliance on adjusted earnings metrics. While leverage concerns have eased and expectations are low, Mesa Laboratories remains a higher-risk bet, but current valuation offers some support. Read the full article on Seeking Alpha
Upcoming Dividend • Nov 21Upcoming dividend of US$0.16 per shareEligible shareholders must have bought the stock before 28 November 2025. Payment date: 15 December 2025. The company is not currently making a profit but it is cash flow positive. Trailing yield: 0.9%. Lower than top quartile of American dividend payers (4.6%). Higher than average of industry peers (0.5%).
Reported Earnings • Nov 07Second quarter 2026 earnings: EPS exceeds analyst expectationsSecond quarter 2026 results: EPS: US$0.45 (down from US$0.63 in 2Q 2025). Revenue: US$60.7m (up 5.0% from 2Q 2025). Net income: US$2.48m (down 28% from 2Q 2025). Profit margin: 4.1% (down from 5.9% in 2Q 2025). The decrease in margin was driven by higher expenses. Revenue was in line with analyst estimates. Earnings per share (EPS) surpassed analyst estimates by 181%. Revenue is forecast to grow 4.7% p.a. on average during the next 3 years, compared to a 6.2% growth forecast for the Life Sciences industry in the US. Over the last 3 years on average, earnings per share has fallen by 42% per year but the company’s share price has only fallen by 25% per year, which means it has not declined as severely as earnings.
分析記事 • Nov 07Mesa Laboratories (NASDAQ:MLAB) Has Announced A Dividend Of $0.16The board of Mesa Laboratories, Inc. ( NASDAQ:MLAB ) has announced that it will pay a dividend of $0.16 per share on...
お知らせ • Nov 07Mesa Laboratories, Inc. Provides Revenue Guidance for the Third Quarter 2026Mesa Laboratories, Inc. provided revenue guidance for the third quarter 2026. For the quarter, the company expect revenues to sequentially increase.
分析記事 • Oct 06Mesa Laboratories (NASDAQ:MLAB) Has Affirmed Its Dividend Of $0.16Mesa Laboratories, Inc. ( NASDAQ:MLAB ) has announced that it will pay a dividend of $0.16 per share on the 15th of...
Declared Dividend • Oct 06First quarter dividend of US$0.16 announcedDividend of US$0.16 is the same as last year. Ex-date: 28th November 2025 Payment date: 15th December 2025 Dividend yield will be 0.9%, which is higher than the industry average of 0.4%. Sustainability & Growth Dividend is being paid despite the company being loss-making over the last 12 months. However, the dividend is well covered by cash flows (11% cash payout ratio). The dividend has not increased over the past 10 years but has been stable with no material reductions to payments, indicating a long track record of dividend stability.
お知らせ • Oct 03+ 1 more updateMesa Laboratories, Inc. to Report Q2, 2026 Results on Nov 06, 2025Mesa Laboratories, Inc. announced that they will report Q2, 2026 results After-Market on Nov 06, 2025
Upcoming Dividend • Aug 22Upcoming dividend of US$0.16 per shareEligible shareholders must have bought the stock before 29 August 2025. Payment date: 15 September 2025. The company is not currently making a profit but it is cash flow positive. Trailing yield: 0.9%. Lower than top quartile of American dividend payers (4.5%). Higher than average of industry peers (0.6%).
分析記事 • Aug 20Mesa Laboratories (NASDAQ:MLAB) Is Paying Out A Dividend Of $0.16Mesa Laboratories, Inc. ( NASDAQ:MLAB ) will pay a dividend of $0.16 on the 15th of September. This means the annual...
New Risk • Aug 13New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of American stocks, typically moving 11% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (11% average weekly change). Significant insider selling over the past 3 months (US$62k sold).
Price Target Changed • Aug 06Price target decreased by 13% to US$105Down from US$120, the current price target is an average from 2 analysts. New target price is 69% above last closing price of US$62.01. Stock is down 48% over the past year. The company is forecast to post earnings per share of US$1.53 next year compared to a net loss per share of US$0.36 last year.
Reported Earnings • Aug 05First quarter 2026 earnings: EPS exceeds analyst expectations while revenues lag behindFirst quarter 2026 results: EPS: US$0.87 (up from US$0.63 in 1Q 2025). Revenue: US$59.5m (up 2.4% from 1Q 2025). Net income: US$4.74m (up 40% from 1Q 2025). Profit margin: 8.0% (up from 5.8% in 1Q 2025). Revenue missed analyst estimates by 1.7%. Earnings per share (EPS) exceeded analyst estimates by 95%. Revenue is forecast to grow 4.6% p.a. on average during the next 2 years, compared to a 6.0% growth forecast for the Life Sciences industry in the US. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 37 percentage points per year, which is a significant difference in performance.
分析記事 • Jul 20It's Down 27% But Mesa Laboratories, Inc. (NASDAQ:MLAB) Could Be Riskier Than It LooksUnfortunately for some shareholders, the Mesa Laboratories, Inc. ( NASDAQ:MLAB ) share price has dived 27% in the last...
分析記事 • Jul 15Mesa Laboratories (NASDAQ:MLAB) Is Due To Pay A Dividend Of $0.16The board of Mesa Laboratories, Inc. ( NASDAQ:MLAB ) has announced that it will pay a dividend of $0.16 per share on...
お知らせ • Jul 14Mesa Laboratories, Inc., Annual General Meeting, Aug 22, 2025Mesa Laboratories, Inc., Annual General Meeting, Aug 22, 2025. Location: mesa laboratories, lakewood, colorado 80228, United States
分析記事 • Jul 07Mesa Laboratories, Inc.'s (NASDAQ:MLAB) Intrinsic Value Is Potentially 32% Above Its Share PriceKey Insights The projected fair value for Mesa Laboratories is US$136 based on 2 Stage Free Cash Flow to Equity Mesa...
Declared Dividend • Jul 06Fourth quarter dividend of US$0.16 announcedDividend of US$0.16 is the same as last year. Ex-date: 29th August 2025 Payment date: 15th September 2025 Dividend yield will be 0.6%, which is higher than the industry average of 0.4%.
お知らせ • Jul 04Mesa Labs Declares Quarterly Dividend, Payable on September 15, 2025Mesa Laboratories, Inc. announced that its Board of Directors has declared a regular quarterly dividend of $0.16 per share of common stock. The dividend will be payable on September 15, 2025, to shareholders of record at the close of business on August 29, 2025.
お知らせ • Jul 03Mesa Laboratories, Inc. to Report Q1, 2026 Results on Aug 05, 2025Mesa Laboratories, Inc. announced that they will report Q1, 2026 results at 8:00 AM, US Eastern Standard Time on Aug 05, 2025
Board Change • Jul 01Insufficient new directorsThere is 1 new director who has joined the board in the last 3 years. The company's board is composed of: 1 new director. 5 experienced directors. 1 highly experienced director. Independent Director Mark Capone was the last director to join the board, commencing their role in 2024. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.
お知らせ • Jun 30+ 7 more updatesMesa Laboratories, Inc.(NasdaqGS:MLAB) dropped from Russell 2000 Value IndexMesa Laboratories, Inc.(NasdaqGS:MLAB) dropped from Russell 2000 Value Index
Recent Insider Transactions Derivative • Jun 18CEO, President & Director notifies of intention to sell stockGary Owens intends to sell 2k shares in the next 90 days after lodging an Intent To Sell Form on the 16th of June. If the sale is conducted around the recent share price of US$97.12, it would amount to US$188k. For the year to March 2019, Gary's total compensation was 14% salary and 86% other compensation. This indicates that these sales could comprise a meaningful part of their income for the year. Since September 2024, Gary's direct individual holding has increased from 36.85k shares to 43.34k. Company insiders have collectively sold US$897k more than they bought, via options and on-market transactions in the last 12 months.
分析記事 • Jun 18We Think Mesa Laboratories (NASDAQ:MLAB) Can Stay On Top Of Its DebtLegendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...
Reported Earnings • May 29Full year 2025 earnings: EPS misses analyst expectationsFull year 2025 results: US$0.36 loss per share (improved from US$47.21 loss in FY 2024). Revenue: US$241.0m (up 12% from FY 2024). Net loss: US$1.97m (loss narrowed 99% from FY 2024). Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates. Revenue is forecast to grow 5.0% p.a. on average during the next 2 years, compared to a 6.1% growth forecast for the Life Sciences industry in the US. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 77 percentage points per year, which is a significant difference in performance.
Upcoming Dividend • May 23Upcoming dividend of US$0.16 per shareEligible shareholders must have bought the stock before 30 May 2025. Payment date: 16 June 2025. The company is not currently making a profit but it is cash flow positive. Trailing yield: 0.6%. Lower than top quartile of American dividend payers (4.8%). In line with average of industry peers (0.7%).
Declared Dividend • Apr 14Third quarter dividend of US$0.16 announcedDividend of US$0.16 is the same as last year. Ex-date: 30th May 2025 Payment date: 16th June 2025 Dividend yield will be 0.6%, which is higher than the industry average of 0.4%.
お知らせ • Apr 08Mesa Laboratories, Inc. Declares Quarterly Dividend, Payable on June 16, 2025Mesa Laboratories, Inc. announced that its Board of Directors has declared a regular quarterly dividend of $0.16 per share of common stock. The dividend will be payable on June 16, 2025, to shareholders of record at the close of business on May 30, 2025.
分析記事 • Apr 01Investors Interested In Mesa Laboratories, Inc.'s (NASDAQ:MLAB) RevenuesWith a median price-to-sales (or "P/S") ratio of close to 2.7x in the Life Sciences industry in the United States, you...
Recent Insider Transactions Derivative • Mar 20CEO, President & Director notifies of intention to sell stockGary Owens intends to sell 21k shares in the next 90 days after lodging an Intent To Sell Form on the 19th of March. If the sale is conducted around the recent share price of US$124, it would amount to US$2.6m. For the year to March 2018, Gary's total compensation was 14% salary and 86% other compensation. This indicates that these sales could comprise a meaningful part of their income for the year. Since June 2024, Gary's direct individual holding has decreased from 114.93k shares to 43.34k. Company insiders have collectively sold US$967k more than they bought, via options and on-market transactions in the last 12 months.
分析記事 • Feb 28At US$135, Is Mesa Laboratories, Inc. (NASDAQ:MLAB) Worth Looking At Closely?Mesa Laboratories, Inc. ( NASDAQ:MLAB ), might not be a large cap stock, but it saw a significant share price rise of...
Upcoming Dividend • Feb 21Upcoming dividend of US$0.16 per shareEligible shareholders must have bought the stock before 28 February 2025. Payment date: 17 March 2025. The company is not currently making a profit but it is cash flow positive. Trailing yield: 0.5%. Lower than top quartile of American dividend payers (4.5%). In line with average of industry peers (0.6%).
Price Target Changed • Feb 07Price target increased by 13% to US$150Up from US$133, the current price target is an average from 3 analysts. New target price is approximately in line with last closing price of US$148. Stock is up 57% over the past year. The company is forecast to post earnings per share of US$1.15 next year compared to a net loss per share of US$47.20 last year.
Reported Earnings • Feb 04Third quarter 2025 earnings: Revenues exceed analysts expectations while EPS lags behindThird quarter 2025 results: US$0.31 loss per share (down from US$0.39 profit in 3Q 2024). Revenue: US$62.8m (up 18% from 3Q 2024). Net loss: US$1.68m (down 179% from profit in 3Q 2024). Revenue exceeded analyst estimates by 6.8%. Earnings per share (EPS) missed analyst estimates. Revenue is forecast to grow 5.0% p.a. on average during the next 3 years, compared to a 5.9% growth forecast for the Life Sciences industry in the US. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 106 percentage points per year, which is a significant difference in performance.
お知らせ • Jan 19Mesa Laboratories, Inc. to Report Q3, 2025 Results on Feb 04, 2025Mesa Laboratories, Inc. announced that they will report Q3, 2025 results at 8:00 AM, Eastern Standard Time on Feb 04, 2025
Declared Dividend • Jan 10Second quarter dividend of US$0.16 announcedDividend of US$0.16 is the same as last year. Ex-date: 28th February 2025 Payment date: 17th March 2025 Dividend yield will be 0.5%, which is about the same as the industry average.
分析記事 • Jan 07Mesa Laboratories, Inc. (NASDAQ:MLAB) Shares Could Be 22% Below Their Intrinsic Value EstimateKey Insights Mesa Laboratories' estimated fair value is US$184 based on 2 Stage Free Cash Flow to Equity Current share...
お知らせ • Jan 07Mesa Laboratories, Inc. Declares Quarterly Dividend, Payable on March 17, 2025Mesa Laboratories, Inc. announced that its Board of Directors has declared a regular quarterly dividend of $0.16 per share of common stock. The dividend will be payable on March 17, 2025, to shareholders of record at the close of business on February 28, 2025.
Seeking Alpha • Dec 19Mesa Laboratories: GKE Acquisition New Crown Jewel, Still Doesn't Move The NeedleSummary Mesa Laboratories' recent acquisition of GKE has improved ROICs, but the legacy business remains a drag on overall performance. Despite improvements, MLAB's valuation risks compression, trading at over 60x trailing EBIT, with an intrinsic worth estimated at $130–145/share. I reiterate a hold rating, with the view the Company is not yet at a turning point, despite promising developments from the GKE acquisition. Read the full article on Seeking Alpha
Upcoming Dividend • Nov 22Upcoming dividend of US$0.16 per shareEligible shareholders must have bought the stock before 29 November 2024. Payment date: 16 December 2024. The company is not currently making a profit but it is cash flow positive. Trailing yield: 0.6%. Lower than top quartile of American dividend payers (4.3%). In line with average of industry peers (0.5%).
分析記事 • Nov 20Investors Give Mesa Laboratories, Inc. (NASDAQ:MLAB) Shares A 25% HidingMesa Laboratories, Inc. ( NASDAQ:MLAB ) shareholders that were waiting for something to happen have been dealt a blow...
Reported Earnings • Nov 08Second quarter 2025 earnings: EPS exceeds analyst expectationsSecond quarter 2025 results: EPS: US$0.63 (up from US$0.23 loss in 2Q 2024). Revenue: US$57.8m (up 8.8% from 2Q 2024). Net income: US$3.43m (up US$4.66m from 2Q 2024). Profit margin: 5.9% (up from net loss in 2Q 2024). Revenue was in line with analyst estimates. Earnings per share (EPS) surpassed analyst estimates significantly. Revenue is forecast to grow 4.4% p.a. on average during the next 3 years, compared to a 6.5% growth forecast for the Life Sciences industry in the US. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 112 percentage points per year, which is a significant difference in performance.
Recent Insider Transactions • Nov 01CEO, President & Director recently sold US$572k worth of stockOn the 29th of October, Gary Owens sold around 5k shares on-market at roughly US$113 per share. This transaction amounted to 10% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. This was Gary's only on-market trade for the last 12 months.
Recent Insider Transactions Derivative • Oct 30CEO, President & Director notifies of intention to sell stockGary Owens intends to sell 3k shares in the next 90 days after lodging an Intent To Sell Form on the 28th of October. If the sale is conducted around the recent share price of US$114, it would amount to US$286k. For the year to March 2018, Gary's total compensation was 14% salary and 86% other compensation. This indicates that these sales could comprise a meaningful part of their income for the year. Since June 2024, Gary's direct individual holding has decreased from 114.93k shares to 36.85k. Company insiders have collectively sold US$395k more than they bought, via options and on-market transactions in the last 12 months.
分析記事 • Oct 17We Think Mesa Laboratories (NASDAQ:MLAB) Can Stay On Top Of Its DebtLegendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...
Declared Dividend • Oct 06First quarter dividend of US$0.16 announcedDividend of US$0.16 is the same as last year. Ex-date: 29th November 2024 Payment date: 16th December 2024 Dividend yield will be 0.5%, which is higher than the industry average of 0.4%.
お知らせ • Oct 03Mesa Laboratories, Inc. Declares Quarterly Dividend, Payable on December 16, 2024Mesa Laboratories, Inc. announced that its Board of Directors has declared a regular quarterly dividend of $0.16 per share of common stock. The dividend will be payable on December 16, 2024, to shareholders of record at the close of business on November 29, 2024.
Recent Insider Transactions Derivative • Sep 16Insider notifies of intention to sell stockBrian Archbold intends to sell 1k shares in the next 90 days after lodging an Intent To Sell Form on the 13th of September. If the sale is conducted around the recent share price of US$125, it would amount to US$187k. Since December 2023, Brian's direct individual holding has increased from 558.00 shares to 1.50k. Company insiders have collectively sold US$395k more than they bought, via options and on-market transactions in the last 12 months.
Price Target Changed • Sep 14Price target increased by 10% to US$130Up from US$118, the current price target is an average from 3 analysts. New target price is approximately in line with last closing price of US$126. Stock is up 2.3% over the past year. The company is forecast to post earnings per share of US$1.51 next year compared to a net loss per share of US$47.20 last year.
分析記事 • Jul 29A Piece Of The Puzzle Missing From Mesa Laboratories, Inc.'s (NASDAQ:MLAB) 27% Share Price ClimbMesa Laboratories, Inc. ( NASDAQ:MLAB ) shareholders would be excited to see that the share price has had a great...
Declared Dividend • Jul 29Fourth quarter dividend of US$0.16 announcedDividend of US$0.16 is the same as last year. Ex-date: 30th August 2024 Payment date: 16th September 2024 Dividend yield will be 0.6%, which is higher than the industry average of 0.4%.
お知らせ • Jul 22Mesa Laboratories, Inc., Annual General Meeting, Aug 30, 2024Mesa Laboratories, Inc., Annual General Meeting, Aug 30, 2024. Location: corporate headquarters at 12100 west sixth avenue, lakewood, colorado 80228., United States
お知らせ • Jul 09Mesa Laboratories, Inc. Declares Quarterly Dividend, Payable on September 16, 2024Mesa Laboratories, Inc. announced that its Board of Directors have declared a regular quarterly dividend of $0.16 per share of common stock. The dividend will be payable on September 16, 2024, to shareholders of record at the close of business on August 30, 2024.
Reported Earnings • Jun 06Full year 2024 earnings: Revenues exceed analysts expectations while EPS lags behindFull year 2024 results: US$47.21 loss per share (down from US$0.17 profit in FY 2023). Revenue: US$216.2m (down 1.3% from FY 2023). Net loss: US$254.2m (down US$255.2m from profit in FY 2023). Revenue exceeded analyst estimates by 2.1%. Earnings per share (EPS) missed analyst estimates significantly. Revenue is forecast to grow 7.2% p.a. on average during the next 3 years, compared to a 6.6% growth forecast for the Life Sciences industry in the US. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 133 percentage points per year, which is a significant difference in performance.
お知らせ • Jun 06Mesa Laboratories, Inc. Reports Impairment of Goodwill and Long-Lived Assets for the Fourth Quarter Ended March 31, 2024Mesa Laboratories, Inc. reported Impairment of goodwill and long-lived assets for the fourth quarter ended March 31, 2024 of $274,533,000.
Upcoming Dividend • May 24Upcoming dividend of US$0.16 per shareEligible shareholders must have bought the stock before 31 May 2024. Payment date: 14 June 2024. The company is paying out more than 100% of its profits but is generating plenty of cash to support the dividend. Trailing yield: 0.6%. Lower than top quartile of American dividend payers (4.7%). Higher than average of industry peers (0.3%).
分析記事 • May 03Is Now An Opportune Moment To Examine Mesa Laboratories, Inc. (NASDAQ:MLAB)?While Mesa Laboratories, Inc. ( NASDAQ:MLAB ) might not have the largest market cap around , it received a lot of...
Declared Dividend • Apr 08Third quarter dividend of US$0.16 announcedDividend of US$0.16 is the same as last year. Ex-date: 31st May 2024 Payment date: 14th June 2024 Dividend yield will be 0.6%, which is higher than the industry average of 0.4%. Payout Ratios Payout ratio: 363%. Cash payout ratio: 8%.
お知らせ • Apr 05Mesa Laboratories, Inc. Declares Regular Quarterly Dividend, Payable on June 14, 2024Mesa Laboratories, Inc. announced that its board of directors has declared a regular quarterly dividend of $0.16 per share of common stock. The dividend will be payable on June 14, 2024, to shareholders of record at the close of business on May 31, 2024.
お知らせ • Apr 02Mesa Laboratories, Inc. to Report Q4, 2024 Results on May 24, 2024Mesa Laboratories, Inc. announced that they will report Q4, 2024 results at 8:00 AM, US Eastern Standard Time on May 24, 2024
分析記事 • Mar 15Is Mesa Laboratories (NASDAQ:MLAB) Using Too Much Debt?Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...
Major Estimate Revision • Mar 10Consensus EPS estimates upgraded to US$0.055 lossThe consensus outlook for fiscal year 2024 has been updated. 2024 losses forecast to reduce from -US$0.08 to -US$0.055 per share. Revenue forecast steady at US$212.8m. Life Sciences industry in the US expected to see average net income growth of 12% next year. Consensus price target of US$127 unchanged from last update. Share price rose 2.3% to US$112 over the past week.
Upcoming Dividend • Feb 21Upcoming dividend of US$0.16 per shareEligible shareholders must have bought the stock before 28 February 2024. Payment date: 15 March 2024. The company is paying out more than 100% of its profits but is generating plenty of cash to support the dividend. Trailing yield: 0.6%. Lower than top quartile of American dividend payers (4.7%). Higher than average of industry peers (0.4%).
分析記事 • Feb 08Mesa Laboratories, Inc. Just Beat Earnings Expectations: Here's What Analysts Think Will Happen NextMesa Laboratories, Inc. ( NASDAQ:MLAB ) last week reported its latest third-quarter results, which makes it a good time...
New Risk • Feb 07New minor risk - Earnings qualityThe company has large one-off items impacting its financial results. One-off items were 154% of the size of the rest of the company's trailing 12-month earnings before tax. This is considered a minor risk. One-off items are incomes or expenses that the company does not expect to repeat in future periods. Examples include profits from the sale of a business or expenses from a restructuring or legal settlements. If the company's reported statutory earnings include a large proportion of one-off items it means they may be an unreliable indicator of its true business performance as the earnings were skewed by these incomes or expenses. Currently, the following risks have been identified for the company: Major Risk Interest payments are not well covered by earnings (0.3x net interest cover). Minor Risk Large one-off items impacting financial results.
Reported Earnings • Feb 05Third quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behindThird quarter 2024 results: EPS: US$0.39 (up from US$0.084 in 3Q 2023). Revenue: US$53.5m (down 1.5% from 3Q 2023). Net income: US$2.12m (up 369% from 3Q 2023). Profit margin: 4.0% (up from 0.8% in 3Q 2023). The increase in margin was driven by lower expenses. Revenue missed analyst estimates by 2.1%. Earnings per share (EPS) exceeded analyst estimates significantly. Revenue is forecast to grow 9.2% p.a. on average during the next 3 years, compared to a 6.1% growth forecast for the Life Sciences industry in the US. Over the last 3 years on average, earnings per share has fallen by 37% per year but the company’s share price has only fallen by 29% per year, which means it has not declined as severely as earnings.
お知らせ • Jan 08Mesa Laboratories, Inc. Appoints Mark Capone to Its Board of DirectorsMesa Laboratories, Inc. announced the appointment of Mark Capone to its Board of Directors, effective January 5, 2024. Following Mr. Capone’s election, the Mesa Board will be comprised of 7 directors, the majority of whom are independent. The Board is committed to ongoing director refreshment and continues to consider new, qualified independent directors. Mr. Capone most recently served as CEO and President of Myriad Genetics for five years. Prior to his appointment as CEO and President, he held various progressive leadership roles at Myriad Genetics, with a total tenure of 17 years at the company. During his leadership tenure, he oversaw Myriad Genetics’ growth from an early-stage pioneer in molecular diagnostics into a leading global precision medicine company. Prior to his tenure at Myriad Genetics, Mr. Capone spent 17 years with Eli Lilly and Company in positions across the entire value chain. In addition to his executive leadership positions, Mr. Capone is a Non-Executive Director and member of the Compensation Committee for of Owlstone Medical Ltd, a breath biopsy diagnostic company focused on early detection of cancer and precision medicine, and a Non-Executive Director and member of the Audit Committee and Financing Committee of DermTech, a U.S. based company focused on early melanoma detection and other skin applications. Previously, Mr. Capone was a director at Abcam PLC, helping to guide that company through its acquisition by Danaher Corporation. Mr. Capone holds a Bachelor of Science in Chemical Engineering from Pennsylvania State University and a M.Sc. in Management and a M.Sc.in Chemical Engineering from Massachusetts Institute of Technology.
お知らせ • Jan 05Mesa Laboratories, Inc. Declares Regular Quarterly Dividend, Payable on March 15, 2024Mesa Laboratories, Inc. announced that on January 2, 2024 its Board of Directors declared a regular quarterly dividend of $0.16 per share of common stock. The dividend will be payable on March 15, 2024, to shareholders of record at the close of business on February 29, 2024.
Recent Insider Transactions Derivative • Dec 18Insider notifies of intention to sell stockBrian Archbold intends to sell 2k shares in the next 90 days after lodging an Intent To Sell Form on the 15th of December. If the sale is conducted around the recent share price of US$116, it would amount to US$174k. Since June 2023, Brian has owned 9.65k shares directly. Company insiders have collectively sold US$1.5m more than they bought, via options and on-market transactions in the last 12 months.
お知らせ • Dec 15Mesa Laboratories, Inc. to Report Q3, 2024 Results on Feb 05, 2024Mesa Laboratories, Inc. announced that they will report Q3, 2024 results at 8:00 AM, US Eastern Standard Time on Feb 05, 2024
分析記事 • Dec 05Is Mesa Laboratories, Inc. (NASDAQ:MLAB) Trading At A 43% Discount?Key Insights The projected fair value for Mesa Laboratories is US$166 based on 2 Stage Free Cash Flow to Equity Mesa...
Upcoming Dividend • Nov 22Upcoming dividend of US$0.16 per share at 0.7% yieldEligible shareholders must have bought the stock before 29 November 2023. Payment date: 15 December 2023. The company is not currently making a profit but it is cash flow positive. Trailing yield: 0.7%. Lower than top quartile of American dividend payers (4.9%). Higher than average of industry peers (0.4%).
Price Target Changed • Nov 09Price target decreased by 17% to US$115Down from US$139, the current price target is an average from 2 analysts. New target price is 23% above last closing price of US$93.73. Stock is down 45% over the past year. The company posted earnings per share of US$0.17 last year.
Reported Earnings • Nov 07Second quarter 2024 earnings: EPS and revenues miss analyst expectationsSecond quarter 2024 results: US$0.23 loss per share (down from US$0.24 profit in 2Q 2023). Revenue: US$53.2m (down 9.5% from 2Q 2023). Net loss: US$1.23m (down 194% from profit in 2Q 2023). Revenue missed analyst estimates by 2.7%. Earnings per share (EPS) were also behind analyst expectations. Revenue is forecast to grow 8.6% p.a. on average during the next 3 years, compared to a 3.9% growth forecast for the Life Sciences industry in the US. Over the last 3 years on average, earnings per share has fallen by 17% per year but the company’s share price has fallen by 30% per year, which means it is performing significantly worse than earnings.
お知らせ • Oct 18Mesa Laboratories, Inc. (NasdaqGS:MLAB) entered into a definitive agreement to acquire Beijing GKE Science & Technology Co. LTD for €5 million.Mesa Laboratories, Inc. (NasdaqGS:MLAB) entered into a definitive agreement to acquire Beijing GKE Science & Technology Co. LTD for €5 million on October 16, 2023. The total purchase price for the acquisition of the entity along with other 2 entities is €85 million, subject to customary purchase price adjustments and holdbacks. Collectively the three entities are referred to as “GKE”. The transactions were or will be funded with proceeds from our credit facility and cash on hand. The transaction is subject to customary conditions, including receipt of applicable Chinese regulatory approvals and is expected to be completed during our third quarter ending December 31, 2023.
お知らせ • Oct 17Mesa Laboratories, Inc. (NasdaqGS:MLAB) acquired Sterilization indicators business of GKE-GmbH and SAL GmbH from Gke-GmbH for €80 million.Mesa Laboratories, Inc. (NasdaqGS:MLAB) acquired Sterilization indicators business of GKE-GmbH and SAL GmbH from Gke-GmbH for €80 million on October 16, 2023. The consideration will be paid in cash and will be funded with proceeds from credit facility and cash on hand. In a related transaction Mesa Laboratories, Inc. (NasdaqGS:MLAB) will acquire Beijing GKE Science & Technology Co. LTD for €5 million. Mesa Laboratories, Inc. (NasdaqGS:MLAB) completed the acquisition of Sterilization indicators business of GKE-GmbH and SAL GmbH from Gke-GmbH on October 16, 2023.
Price Target Changed • Oct 05Price target decreased by 8.9% to US$139Down from US$153, the current price target is an average from 2 analysts. New target price is 40% above last closing price of US$98.95. Stock is down 31% over the past year. The company is forecast to post earnings per share of US$0.68 for next year compared to US$0.17 last year.